Firms

Jeito Capital

Jeito Capital

Paris, France · London, United Kingdom

jeito.life

Jeito Capital is an independent biopharma investment manager founded by physician-scientist Rafaèle Tordjman in2018, with a continuous-financing strategy supporting clinical-stage therapeutics through development and commercialization. The exact legal manager is Jeito Capital SAS, RCS Paris839611449/VATFR51839611449, authorised by the French AMF underGP-19000043. Its Paris-led multidisciplinary public team spans investment, clinical/translational science, regulatory, commercial, talent and operating functions, with London investment leadership. Neuroscience and neuromuscular exposure includes Noema and Augustine Therapeutics. Current public English directory names32 people, including external finance adviser AlainRougon; biographies not on current directory do not imply present employment. JeitoI closed EUR534M announcedSeptember20,2021. JeitoII final-close March31,2026 was above EUR1B, announcedApril8,2026; exact undisclosed total remainsNULL rather than being inferred from target or FX-rounded USD1.2B. Reported EUR1.6B AUM is not another fund or cash close. Existing investments, fund references, shared people and personal attribution are preserved.

Founded
2018
Type
Venture capital

Funds2

  • Jeito II S.L.P.—
  • Jeito S.L.P. (Jeito I)€534M

Team

Operations and support

Alain RougonAlain RougonFinance Advisor (external provider, Prodensia)
Ana Leticia MaragnoAna Leticia MaragnoDirector of Translational science
Anastasiya SybirnaAnastasiya SybirnaPrincipal
Annette ClancyAnnette ClancyOperating Partner, M&A & Strategy
Benjamin CaillierBenjamin CaillierFinance Director, Jeito Capital
Boris KereBoris KereCompliance Officer
Charlotte FormontCharlotte FormontHead of Legal
Chloé MorlaàsChloé MorlaàsInvestor Relations Director
Chloé RocheChloé RocheAnalyst
Claudio Costa-NetoClaudio Costa-NetoPartner & Chief Scientific Officer
Daniel WolleDaniel WollePrincipal
Elana LockshinElana LockshinAnalyst
Estelle RuotteEstelle RuotteFinance Manager, Fund
Evaldo Bifulco Jr.Evaldo Bifulco Jr.Head of Sustainability, Compliance & Risk (RCCI)
Henri MazeauHenri MazeauLegal Counsel
Hortense de MeauxHortense de MeauxFinance Manager, Fund
Ivana TrivunovicIvana TrivunovicAnalyst
Jessica FadelJessica FadelExecutive Assistant of Founder and CEO
Karin van BaelenKarin van BaelenChief Regulatory Advisor
Ksenija PavleticKsenija PavleticGeneral Partner & Chief Commercial Officer
Magdalena JonikasMagdalena JonikasPartner
Manon FrachonManon FrachonProject Manager
Maya ChkaibanMaya ChkaibanPrincipal
Mehdi AinoucheMehdi AinouchePartner
Noémie TimsitNoémie TimsitAssociate
Olga GolushkoOlga GolushkoExecutive Assistant
Pascal TouchonPascal TouchonPartner
Rafaèle TordjmanRafaèle TordjmanFounder & CEO
Sabine DandiguianSabine DandiguianManaging Partner
Samit HirawatSamit HirawatOperating Partner, Medical Strategy
Sarah Oliver RicomeSarah Oliver RicomeExecutive Assistant
Sarah ShackeltonSarah ShackeltonPartner, Talent

Co-investing

Novo Holdings
Alpha Wave Global
ARCH Venture Partners
Arkin Bio Capital
Forbion

Investments

$—2025-03-24Augustine TherapeuticsNovo Holdings, Jeito Capital, AdBio Partners, PMV (Participatiemaatschappij Vlaanderen), Gemma Frisius Fund, Asabys Partners, Newton Biocapital, V-Bio Ventures, Eli Lilly and Company, CMT Research Foundation, VIB (Flanders Institute for Biotechnology)
CHF 27M2024-12-11Noema PharmaEQT Life Sciences, Forbion, Jeito Capital, UPMC Enterprises, Sofinnova Partners, Polaris Partners, Gilde Healthcare, The Invus Group, LLC, BioMedPartners
$95M2024-01-04HI-BioARCH Venture Partners, Viking Global Investors, Alpha Wave Global, Jeito Capital, Arkin Bio Capital
$95M2024-01-04Human Immunology Biosciences (HI-Bio)ARCH Venture Partners, Viking Global Investors, Alpha Wave Global, Jeito Capital, Arkin Bio Capital
€75M2023-11-15NMD PharmaJeito Capital, Novo Holdings, INKEF Capital, Lundbeckfond Invest A/S, Roche Venture Fund
CHF 103M2023-03-07Noema PharmaForbion, Jeito Capital, UPMC Enterprises, Sofinnova Partners, Polaris Partners, Gilde Healthcare, The Invus Group, LLC
$65M2022-02-22Eyebiotech LimitedSV Health Investors, Samsara BioCapital, Jeito Capital, MRL Ventures
€35M2022-02-15NMD PharmaJeito Capital, Novo Holdings, INKEF Capital, Lundbeckfond Invest A/S, Roche Venture Fund
$85M2021-04-21HiveGeneral Catalyst, Glynn Capital, Jeito Capital
$65MUnknown dateEyebiotech LimitedBain Capital, MRL Ventures Fund, SV Health Investors, Omega Funds, Jeito Capital, Vertex Ventures HC